- Home
- GMAB vs TECK Comparison
GMAB vs TECK Comparison
Compare GMAB & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TECK
- Stock Information
- Founded
- GMAB 1999
- TECK 1913
- Country
- GMAB Denmark
- TECK Canada
- Employees
- GMAB N/A
- TECK N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TECK
- Sector
- GMAB Health Care
- TECK
- Exchange
- GMAB Nasdaq
- TECK Nasdaq
- Market Cap
- GMAB 12.8B
- TECK N/A
- IPO Year
- GMAB N/A
- TECK N/A
- Fundamental
- Price
- GMAB $20.95
- TECK $37.05
- Analyst Decision
- GMAB Buy
- TECK Strong Buy
- Analyst Count
- GMAB 9
- TECK 9
- Target Price
- GMAB $39.17
- TECK $63.78
- AVG Volume (30 Days)
- GMAB 1.5M
- TECK 3.1M
- Earning Date
- GMAB 05-08-2025
- TECK 07-23-2025
- Dividend Yield
- GMAB N/A
- TECK 1.96%
- EPS Growth
- GMAB 276.13
- TECK N/A
- EPS
- GMAB 18.36
- TECK 0.59
- Revenue
- GMAB $3,230,902,140.00
- TECK $6,773,576,370.00
- Revenue This Year
- GMAB $17.69
- TECK $16.66
- Revenue Next Year
- GMAB $14.81
- TECK $11.40
- P/E Ratio
- GMAB $11.30
- TECK $61.12
- Revenue Growth
- GMAB 25.21
- TECK 125.89
- 52 Week Low
- GMAB $17.24
- TECK $28.32
- 52 Week High
- GMAB $28.96
- TECK $54.13
- Technical
- Relative Strength Index (RSI)
- GMAB 55.72
- TECK 54.39
- Support Level
- GMAB $20.73
- TECK $37.00
- Resistance Level
- GMAB $21.42
- TECK $38.13
- Average True Range (ATR)
- GMAB 0.45
- TECK 0.94
- MACD
- GMAB 0.11
- TECK 0.17
- Stochastic Oscillator
- GMAB 81.62
- TECK 55.15
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.